Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer

Oncology Letters

Volumn 6, Issue 2, 2013, Pages 437-441

  Murugan, Avaniyapuram Kannan ^a   Yang, Chongfei ^a   Xing, Michael Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FGD1; GNA11; GRM3; MMP27; Mutation; Thyroid cancer; TRRAP

Indexed keywords

ANAPLASTIC THYROID CANCER; ARTICLE; CARCINOGENESIS; FGD1 GENE; GENE; GENE MUTATION; GENE SEQUENCE; GNA11 GENE; GRM3 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MATRIX METALLOPROTEINASE 27 GENE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; TRRAP GENE;

EID: 84879484844     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1391     Document Type: Article

References (19)

1. Leenhardt L, Grosclaude P and Chérié-Challine L; Thyroid Cancer Committee: Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14: 1056-1060, 2004.
2. Sprague BL, Warren Andersen S and Trentham-Dietz A: Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes Control 19: 585-593, 2008.
3. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262, 2005.
4. Liu Z, Hou P, Ji M, et al: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93: 3106-3116, 2008.
5. Van Raamsdonk CD, Griewank KG, Crosby MB, et al: Mutations in GNA11 in uveal melanoma. N Engl J Med 363: 2191-2199, 2010.
6. Palavalli LH, Prickett TD, Wunderlich JR, et al: Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 41: 518-520, 2009.
7. Wei X, Walia V, Lin JC, et al: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43: 442-446, 2011.
8. Prickett TD, Wei X, Cardenas-Navia I, et al: Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43: 1119-1126, 2011.
9. Hou P, Liu D and Xing M: Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer 18: 687-697, 2011.
10. Brinckerhoff CE and Matrisian LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3: 207-214, 2002.
11. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
12. Freije JM, Balbín M, Pendás AM, Sánchez LM, Puente XS and López-Otín C: Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 532: 91-107, 2003.
13. Orrico A, Galli L, Faivre L, et al: Aarskog-Scott syndrome: clinical update and report of nine novel mutations of the FGD1 gene. Am J Med Genet A 152A: 313-318, 2010.
14. Whitehead IP, Abe K, Gorski JL and Der CJ: CDC42 and FGD1 cause distinct signaling and transforming activities. Mol Cell Biol 18: 4689-4697, 1998.
15. Murugan AK, Dong J, Xie J and Xing M: MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle 8: 2122-2124, 2009.
16. Murugan AK and Xing M: Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 71: 4403-4411, 2011.
17. Neff RL, Farrar WB, Kloos RT and Burman KD: Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 37: 525-538, 2008.
18. Murugan AK, Dong J, Xie J and Xing M: Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr Pathol 22: 97-102, 2011.
19. Mitsiades CS, Kotoula V, Poulaki V, et al: Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 91: 3662-3666, 2006.